Isatuximab
- Generic Name
- Isatuximab
- Brand Names
- Sarclisa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1461640-62-9
- Unique Ingredient Identifier
- R30772KCU0
- Background
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on th...
- Indication
Isatuximab is indicated in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also indicated in combination carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple ...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Isatuximab in Adult Patients with Cytologic or Molecular Relapsed/refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 40
- Registration Number
- NCT06648889
- Locations
- 🇩🇪
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie, Berlin, Germany
🇩🇪University Hospital Erlangen AöR, Department of Medicine 5, Erlangen, Germany
🇩🇪Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology, Frankfurt am Main, Germany
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 40
- Registration Number
- NCT06517017
- Locations
- 🇺🇸
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 411
- Registration Number
- NCT06216158
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie, Berlin, Germany
🇩🇪Helios Klinikum Berlin-Buch, Berlin, Germany
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05922501
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT05911321
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Isatuximab in Lung Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 6
- Registration Number
- NCT05862766
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 514
- Registration Number
- NCT05804032
- Locations
- 🇦🇹
Phyrn-Eisenwurzen Klinikum Steyr, Steyr, Austria
🇦🇹Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz, Salzburg, Austria
🇩🇪Charité, III. Medizinische Abteilung (Hämatologie/Onkologie), Berlin, Germany
Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT05776979
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia
Elimination of Minimal Residual Disease After Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 31
- Registration Number
- NCT05690984
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.